| Expression pattern: |
UP |
| Associated gene: |
METTL3, SOX2, Ago2 |
| Associated microRNA: |
miR-524-5p |
| Biological function: |
Facilitates proliferation, sphere formation (stemness), migration, invasion and cisplatin resistance; suppresses apoptosis; disseminates malignant properties and cisplatin resistance via exosomal transfer. |
| Molecular mechanism: |
Acts as a miR-524-5p sponge to up-regulate METTL3 and SOX2; increases SOX2 m6A modification and stability through METTL3; transmitted through exosomes to recipient cells to confer cisplatin resistance. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); EMT (promotes); chemoresistance (promotes); m6A modification (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; Nuclear-Cytoplasmic Fractionation; Bioinformatics Analysis; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Sphere Formation Assay; Wound Healing Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; MeRIP / MeRIP-seq; Actinomycin D / DRB Stability Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Clinical Sample Validation |
| Clinical significance: |
Serum exosomal circVMP1 is up-regulated in DDP-resistant NSCLC patients and may serve as a biomarker for DDP resistance. |
| Description: |
circVMP1 is up-regulated in cisplatin-resistant NSCLC cells and serum exosomes from DDP-resistant patients. It promotes malignant phenotypes and cisplatin resistance by sponging miR-524-5p to increase METTL3 and SOX2 (including METTL3-mediated m6A and SOX2 stability), and can be transferred via exosomes to confer resistance to sensitive cells. |
| Confidence score: |
0.8785 |